Brokerages Anticipate Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) to Announce -$0.04 Earnings Per Share

Equities analysts expect Diffusion Pharmaceuticals Inc. (NASDAQ:DFFNGet Rating) to report earnings per share (EPS) of ($0.04) for the current quarter, according to Zacks. Zero analysts have provided estimates for Diffusion Pharmaceuticals’ earnings, with estimates ranging from ($0.04) to ($0.03). Diffusion Pharmaceuticals posted earnings of ($0.06) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Diffusion Pharmaceuticals will report full-year earnings of ($0.16) per share for the current financial year, with EPS estimates ranging from ($0.17) to ($0.14). For the next fiscal year, analysts expect that the business will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.15) to ($0.13). Zacks’ EPS calculations are an average based on a survey of research firms that follow Diffusion Pharmaceuticals.

Several research firms recently issued reports on DFFN. StockNews.com initiated coverage on Diffusion Pharmaceuticals in a research report on Tuesday. They issued a “sell” rating on the stock. HC Wainwright reissued a “neutral” rating on shares of Diffusion Pharmaceuticals in a research note on Thursday, April 7th.

Diffusion Pharmaceuticals stock traded down $0.29 during mid-day trading on Thursday, reaching $8.27. 12,012 shares of the company were exchanged, compared to its average volume of 1,191,429. Diffusion Pharmaceuticals has a 12-month low of $0.17 and a 12-month high of $0.86. The business has a fifty day moving average of $0.25 and a 200 day moving average of $0.33. The firm has a market cap of $842.92 million, a P/E ratio of -26.88 and a beta of 1.46.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of Diffusion Pharmaceuticals during the 4th quarter worth approximately $46,000. Citadel Advisors LLC acquired a new stake in shares of Diffusion Pharmaceuticals during the 2nd quarter worth approximately $110,000. Renaissance Technologies LLC increased its holdings in shares of Diffusion Pharmaceuticals by 8.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,223,102 shares of the company’s stock worth $373,000 after buying an additional 97,600 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Diffusion Pharmaceuticals by 6.7% during the 3rd quarter. Geode Capital Management LLC now owns 858,408 shares of the company’s stock worth $437,000 after buying an additional 54,118 shares during the last quarter. 9.09% of the stock is currently owned by institutional investors and hedge funds.

Diffusion Pharmaceuticals Company Profile (Get Rating)

Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor.

Featured Stories

Get a free copy of the Zacks research report on Diffusion Pharmaceuticals (DFFN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.